Changing Treatment Paradigms for Myelodysplastic Syndromes in a Community Oncology Practice: Georgia Cancer Specialists' Experience

Abstract Background Criteria for adoption of new therapies and treatment paradigms in community oncology practices can differ substantively from that of academic medical centers. Differences arise, in part, from the influence of patient mix, available resources and services offered, physician/staff experiences, and the adherence to uniform treatment guidelines. Georgia Cancer Specialists (GCS) is a 31-site community-based group practice with 41 hematologists/oncologists motivated to standardize medical decision-making and optimize patient outcomes and health-care resource utilization. Patients and Methods Using our integrated electronic medical records and billing database (OASIS), we conducted a retrospective evaluation to assess the impact of 3 new agents (decitabine, 5-azacitidine, and lenalidomide) on practice patterns and outcomes in an elderly population with myelodysplastic syndrome (MDS) in the community setting. From January 2006 to June 2007, data from 1161 patients with MDS (mean age, 71 years; 63% women; 60% Medicare/Medicaid recipients) were collected. Of these, 76 patients (6.5%) received ≥ 1 MDS-indicated therapeutic agent (47% decitabine, 32% 5-azacitidine, 46% lenalidomide; 25% received ≥ 2 agents) for a median of 3, 2, and 3 cycles, respectively. Results In general, the data suggest that patients receiving MDS-therapeutic agents had hematologic improvement and experienced reductions in transfusion requirements. The GCS population and treatment-related data reflect the uptake of new MDS therapeutic agents introduced proactively into a real-world community oncology practice and supplements information from randomized clinical trials. Conclusion Data derived from the community setting have the potential to provide important insights about actual disease prevalence, patient demographics, factors that influence medical careseeking, clinical management, and outcomes outside of academic institutions.

[1]  J. Reeves,et al.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. , 2008, Blood.

[2]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[3]  Sonali M. Smith,et al.  Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation , 2007, Bone Marrow Transplantation.

[4]  A. Jemal,et al.  Cancer mortality in the United States by education level and race. , 2007, Journal of the National Cancer Institute.

[5]  A. Raza,et al.  Current Treatment Options: Impact of Cytogenetics on the Course of Myelodysplasia , 2007, Current treatment options in oncology.

[6]  M. Tomonaga,et al.  Retrospective nationwide survey of Japanese patients with transfusion‐dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality , 2007, European journal of haematology.

[7]  E. Estey,et al.  Acute myeloid leukemia and myelodysplastic syndromes in older patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Mayne,et al.  Myelodysplastic syndromes , 2007, Cancer.

[9]  M. L. Thomas.  Strategies for achieving transfusion independence in myelodysplastic syndromes. , 2007, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[10]  J. Issa,et al.  Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome , 2007, Cancer.

[11]  C. Schiffer.  Myelodysplasia: the good, the fair and the ugly. , 2007, Best practice & research. Clinical haematology.

[12]  H. Kantarjian,et al.  The role of decitabine in the treatment of myelodysplastic syndromes , 2007, Expert opinion on pharmacotherapy.

[13]  J. Issa,et al.  Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.

[14]  Herschel Knapp,et al.  Lay patient navigator program implementation for equal access to cancer care and clinical trials , 2006, Cancer.

[15]  T. Cosgriff,et al.  Hematologic Improvement, Transfusion Independence, and Safety Assessed Using Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes. , 2006 .

[16]  R. Mertelsmann,et al.  Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. , 2006, Haematologica.

[17]  A. List,et al.  Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes. , 2006, Current pharmaceutical biotechnology.

[18]  R. Larson,et al.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[20]  M. Lübbert,et al.  Superiority of prolonged low‐dose azanucleoside administration? , 2006, Cancer.

[21]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[22]  H. Møller,et al.  The incidence and outcome of myeloid malignancies in 2,112 adult patients in South East-England. , 2006 .

[23]  C. Bloomfield,et al.  Myelodysplastic syndromes clinical practice guidelines in oncology. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[24]  J. Schulte‐Mönting,et al.  Comparison of five prognostic scoring systems, the French–American–British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis , 2006, Annals of Hematology.

[25]  J. Bennett.  A comparative review of classification systems in myelodysplastic syndromes (MDS). , 2005, Seminars in oncology.

[26]  M. Sekeres,et al.  Alternative treatments for myelodysplastic syndromes. , 2005, Seminars in hematology.

[27]  L. Rimsza,et al.  Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.

[28]  Harlan M Krumholz,et al.  Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.

[29]  L. Balducci.  Anemia, cancer, and aging. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[30]  M. Christian,et al.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Kelly,et al.  'More than just money' -- widening the understanding of the costs involved in cancer care. , 2001, Journal of advanced nursing.

[32]  I. Jaiyesimi,et al.  Myelodysplastic syndrome at a large tertiary care community hospital: analysis according to the international prognostic scoring system. , 2000, Leukemia research.

[33]  R. Costabile.  Cancer and male sexual dysfunction. , 2000, Oncology.

[34]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[35]  D. Cella,et al.  Age and clinical decision making in oncology patients. , 1994, Journal of the National Cancer Institute.

[36]  A. Gratwohl,et al.  Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) , 1990, British journal of haematology.